Peptide Biologix
Compound index
The atlas

GHK-Cu (Copper Peptide): Comprehensive Research Monograph

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex) is an endogenous human plasma matrikine tripeptide-metal chelate liberated from SPARC/osteonectin during extracellular matrix remodeling, characterized by femtomolar Cu(II) affinity, square-planar coordination geometry, and broad transcriptional modulation across more than 4,000 human genes.

Engraved cross-section of layered stone with a small green mineral seam
Plate 9GHK-Cu
Class I — Regenerative & Repair · MW 402.92 g/mol · Copper Tripeptide-1, Glycyl-L-Histidyl-L-Lysine:Copper(II)
AA Sequence (Tripeptide Metallocomplex) Gly-His-Lys · Cu(II) [1:1 Square-Planar Complex, λmax = 246 nm]
Regulatory & Compounding Status (April 2026)

Topical GHK-Cu (INCI: Copper Tripeptide-1) is regulated as a cosmetic ingredient when marketed for topical appearance applications, whereas injectable GHK-Cu is not an FDA-approved drug product. FDA's page current as of April 22, 2026 lists GHK-Cu (for injectable routes) as nominated but withdrawn. All data in this monograph are provided strictly for in vitro and preclinical laboratory research.

1. Molecular Characterization

1.1 Chemical Structure and Identity

Glycyl-L-histidyl-L-lysine copper(II) complex (GHK-Cu) is a naturally occurring tripeptide-metal chelate characterized by its high-affinity coordination with cupric ions. The peptide sequence consists of glycine (Gly), L-histidine (His), and L-lysine (Lys) residues arranged in the N-terminal to C-terminal configuration Gly-His-Lys. This tripeptide demonstrates high selectivity for copper(II) ions with a dissociation constant (Kd) in the femtomolar range, establishing it as a major physiological copper-transporting matrikine in human plasma.

Table 1: Physicochemical Properties of GHK-Cu
Property Value Method of Determination
Molecular Formula (Free GHK Ligand) C14H24N6O4 Mass Spectrometry
Molecular Formula (GHK-Cu Complex) C14H24N6O4·Cu ESI-MS / Elemental Analysis
Molecular Weight (Free GHK) 340.38 Da MS Analysis
Molecular Weight (GHK-Cu Complex) 404.93 Da MS Analysis
Copper Binding Ratio 1:1 (peptide:Cu2+) UV-Vis Spectroscopy / Job's Plot
Kd (Dissociation Constant) ~10-16 M Equilibrium Dialysis / Potentiometry
λmax (Charge-Transfer Absorption) 246 nm (ε246 ≈ 8,900 M-1cm-1) UV-Vis Spectroscopy
Sequence Gly-His-Lys Edman Degradation / MS/MS
Isoelectric Point 7.8–8.2 Isoelectric Focusing

1.2 Coordination Chemistry

Structural elucidation through X-ray crystallography, electron paramagnetic resonance (EPR) spectroscopy, X-ray absorption spectroscopy (XAS), and nuclear magnetic resonance (NMR) spectroscopy has definitively characterized the coordination environment of the Cu(II) ion within the GHK-Cu complex. The copper center adopts a square planar geometry with four coordinate bonds: the imidazole nitrogen from the histidine side chain (Nim), the α-amino nitrogen from the N-terminal glycine residue (Nα), and two deprotonated amide nitrogens from the peptide backbone connecting glycine-histidine and histidine-lysine residues (N-). This tetradentate coordination creates a thermodynamically stable chelate with remarkable resistance to ligand exchange under physiological conditions.

X-ray absorption near-edge spectroscopy (XANES) studies confirm that copper maintains its +2 oxidation state within the complex under standard physiological pH (7.2–7.4), though the coordination geometry facilitates electron transfer reactions critical to the peptide's biological activities. The lysine residue, while not directly coordinating the metal center, contributes to the overall stability through electrostatic interactions and may participate in receptor binding or membrane translocation events.

1.3 Plasma Concentration and Age-Related Decline

Endogenous GHK concentrations in human plasma exhibit significant age-dependent variation. Quantitative analysis via liquid chromatography-mass spectrometry (LC-MS) demonstrates mean plasma concentrations of approximately 200 ng/mL (590 nM) in healthy individuals aged 20–25 years. This concentration progressively declines with advancing age, reaching approximately 80 ng/mL (235 nM) by age 60, representing a 60% reduction over four decades. This age-associated depletion correlates with diminished wound healing capacity, reduced collagen synthesis, and decreased tissue regeneration efficiency observed in elderly populations, suggesting a mechanistic link between GHK availability and age-related physiological decline.

1.4 Biological Origin and Release Mechanisms

GHK originates as a cryptic peptide sequence within the extracellular matrix protein SPARC (secreted protein acidic and rich in cysteine), also designated as osteonectin or basement membrane protein 40 (BM-40). Matrix metalloproteinase (MMP)-mediated proteolysis of SPARC during tissue remodeling, wound healing, and inflammation liberates the GHK sequence into the local microenvironment and systemic circulation. This release mechanism couples tissue damage or remodeling signals with the availability of regenerative peptide mediators, creating a feedback system that promotes tissue repair and homeostasis.

2. Chemical Synthesis and Manufacturing

2.1 Solid-Phase Peptide Synthesis

Contemporary commercial production of GHK employs Fmoc (9-fluorenylmethoxycarbonyl) solid-phase peptide synthesis (SPPS) methodology, which enables efficient, high-purity synthesis of short peptide sequences. The synthesis proceeds on a solid resin support with sequential coupling of protected amino acids in the C-terminal to N-terminal direction. Fmoc-Lys(Boc)-OH serves as the first residue coupled to the resin, followed by Fmoc-His(Trt)-OH and Fmoc-Gly-OH. Standard coupling reagents including HBTU, HOBt, and DIPEA facilitate amide bond formation with high efficiency and minimal racemization.

2.2 Cleavage, Purification, and Copper Complexation

Following chain assembly, the peptide undergoes simultaneous cleavage from the resin and side-chain deprotection using trifluoroacetic acid (TFA) cocktails containing scavengers such as triisopropylsilane (TIS), water, and ethanedithiol (EDT). Crude peptide purification employs reversed-phase high-performance liquid chromatography (RP-HPLC) using C18 columns with acetonitrile-water gradients containing 0.1% TFA. Copper complexation occurs post-purification through controlled stoichiometric addition (1:1 molar ratio) of copper(II) salts to aqueous GHK solutions at physiological pH, monitored by UV-Vis spectroscopy through the characteristic 246 nm absorption band.

2.3 Recombinant Expression Systems

Alternative production methodologies utilizing recombinant DNA technology incorporating the GHK sequence within fusion proteins in Escherichia coli or yeast hosts have been developed, though solid-phase synthesis remains the predominant industrial method due to the tripeptide's short length and straightforward synthesis profile.

3. Molecular Mechanisms of Action

3.1 Receptor-Mediated Signaling

GHK-Cu interacts with cell-surface integrins (β1 and α6 integrins in basal keratinocytes) and heparan sulfate proteoglycans, activating mitogen-activated protein kinases (ERK1/2, p38 MAPK), PI3K/Akt, and TGF-β/Smad2/3 signaling cascades.

3.2 Copper Trafficking and Redox Regulation

GHK-Cu functions as a physiological copper chaperone that delivers bioavailable Cu(II) to copper-dependent metalloenzymes—most notably lysyl oxidase (LOX), which catalyzes covalent cross-linking of collagen and elastin fibrils, and Cu/Zn superoxide dismutase (SOD1).

3.3 Comprehensive Gene Expression Modulation

Microarray analysis conducted by the Broad Institute using the Connectivity Map (CMap) database revealed that GHK treatment alters expression patterns of approximately 31.7% of the entire human genome—affecting over 4,000 individual genes:

Table 2: Gene Expression Modulation by GHK-Cu
Gene Category Effect Number of Genes Affected Functional Outcome
DNA Repair Genes Upregulation 47 genes Enhanced genomic stability
Antioxidant Genes Upregulation 33 genes Oxidative stress protection
Caspase/Apoptosis Genes Upregulation 10 caspase genes Improved apoptotic clearance
Growth Factors (VEGF, bFGF) Upregulation 12 genes Enhanced angiogenesis
Collagen Genes Upregulation Multiple collagen types ECM synthesis
Pro-inflammatory Cytokines Downregulation 18 genes Anti-inflammatory response
Pro-fibrotic Genes Downregulation 23 genes Reduced pathological fibrosis
Metastasis-Associated Genes Downregulation Multiple oncogenes Anti-cancer potential

3.4 Tissue-Specific Gene Regulation

Analysis of disease-specific gene signatures demonstrates GHK-Cu's capacity to reverse pathological expression patterns. In metastasis-prone colon cancer cell lines, GHK treatment reversed the expression of 70% of genes comprising the metastatic signature, shifting cells toward a less aggressive phenotype. In chronic obstructive pulmonary disease (COPD) lung tissue models, GHK modified gene expression from patterns associated with tissue destruction toward those characteristic of healthy tissue remodeling and repair. These findings suggest epigenetic mechanisms may contribute to GHK's actions, though direct evidence for histone modification or DNA methylation changes requires further investigation.

3.5 Specific Molecular Pathways

At the molecular pathway level, GHK-Cu activates transforming growth factor-β (TGF-β) signaling through Smad2/3 phosphorylation, promoting fibroblast-to-myofibroblast differentiation essential for wound contraction. The peptide stimulates secretion of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) at nanomolar concentrations (1–10 nM), driving angiogenesis through endothelial cell proliferation and migration. Upregulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) creates a balanced proteolytic environment conducive to extracellular matrix remodeling without excessive degradation.

4. Preclinical Research Findings

4.1 Wound Healing & Ischemic Skin Flap Models

In full-thickness ischemic skin flap wounds in Sprague-Dawley rats, daily topical GHK-Cu treatment for 13 days achieved a 64.5% reduction in wound area compared to 45.6% in vehicle controls and 28.2% in untreated controls, accompanied by elevated SOD, catalase, and glutathione peroxidase activity and a 9-fold increase in granulation tissue collagen in streptozotocin-diabetic rat wounds.

4.2 Systemic Regenerative Effects

Preclinical studies in rats, mice, and pigs demonstrated that parenteral administration of GHK-Cu at one anatomical site (e.g., thigh muscle at 1.1 mg/kg in pigs) accelerated wound closure and collagen deposition at distant anatomical sites (contralateral ear wounds), confirming systemic matrikine signaling.

4.3 Neurocognitive & Anti-Cancer Preclinical Models

Age-related cognitive decline represents an active preclinical research area in which GHK demonstrates preliminary potential. Aged C57BL/6 mice (28 months old) administered GHK at 10 mg/kg 5 times weekly for 3 weeks showed improved spatial learning performance in the Morris water maze compared to saline controls. In MCF7 breast and PC3 prostate cancer cell cultures (1 μM), GHK upregulated 10 caspase-associated genes and 84 DNA repair/cell-cycle genes.

Table 3: Preclinical Efficacy Data Summary Literature summary of published study doses, routes, and schedules.
Model System Dose / Concentration Duration Primary Outcome Magnitude of Effect
Rat Ischemic Skin Flap Wound Topical GHK-Cu hydrogel 13 days Wound area reduction 64.5% vs. 28.2% untreated control
Diabetic Rat Excisional Wound Collagen dressing + GHK-Cu 14 days Granulation collagen content 9-fold increase over control
Rabbit Excisional Wound + HeNe Laser Topical GHK-Cu 10 days Granulation & antioxidant enzymes Significant increase in SOD/catalase
Aged C57BL/6 Mice (28 months) 10 mg/kg SC (5x/week) 3 weeks Morris water maze spatial learning Statistically significant improvement
Porcine Distant Wound Model 1.1 mg/kg IM Single / short course Remote wound closure Systemic healing enhancement
Human Dermal Fibroblasts 1 pM – 1 nM 48–72 hours Procollagen type I synthesis Maximal stimulation at 1 nM
MCF7 / PC3 Cancer Cell Lines 1 μM 24–48 hours Transcriptomic profiling Upregulation of 10 caspase & 84 DNA repair genes
Zebrafish Embryo Cu Toxicity Recombinant GHK 96 hours Cardioprotection Attenuation of free Cu2+ cardiotoxicity

5. Clinical Studies and Human Data

5.1 Dermatological Photoaging & Dermal Thickness Trials

In a randomized, double-blind, vehicle-controlled 8-week trial (n=67 women aged 45–60), twice-daily topical GHK-Cu nano-lipid carrier application reduced wrinkle volume by 31.6% vs. baseline (7.2% vehicle, p<0.001) and reduced transepidermal water loss (TEWL) by 18.4%. In a 12-week high-frequency ultrasound (20 MHz) and punch-biopsy study (n=23, mean age 62), topical copper tripeptide increased epidermal thickness by 15.7% (p=0.004), dermal thickness by 22.3% (p<0.001), and immunohistochemical collagen I staining area by 41%.

5.2 Collagen Type IV Synergy & Chronic Ulcer Studies

Cangul et al. (2023) demonstrated that a 1:9 ratio of GHK-Cu to low-molecular-weight hyaluronic acid increased collagen type IV mRNA expression by 25.4-fold in human dermal fibroblasts and collagen IV protein by 2.03-fold in ex vivo human skin explants. In a controlled diabetic foot ulcer study (n=32), topical GHK-Cu gel accelerated epithelialization by 21% over 4 weeks compared to standard care.

Table 4: Summary of Human Dermatological & Ex Vivo Studies
Study Design Population (n) Intervention Duration Primary Endpoint Result
RCT, Double-Blind Women, 45–60 (n=67) GHK-Cu nano-lipid carrier, BID 8 weeks Wrinkle volume (optical profilometry) 31.6% reduction vs. baseline (p<0.001)
Ultrasound + Biopsy Pilot Adults, mean age 62 (n=23) Topical Cu-tripeptide, BID 12 weeks 20 MHz ultrasound thickness & IHC Epidermis +15.7%, Dermis +22.3%, Collagen I +41%
Ex Vivo + In Vitro Human skin explants & fibroblasts GHK-Cu + LMW HA (1:9) 72 hours Collagen IV mRNA & ELISA 25.4-fold (cell), 2.03-fold (tissue)
Controlled Clinical Study Diabetic foot ulcers (n=32) Topical GHK-Cu gel vs. standard care 4 weeks Epithelialization rate 21% faster closure vs. control
Open-Label Phototrichogram Androgenetic alopecia (n=32) Topical GHK-Cu solution, BID 12 weeks Hair density & shaft diameter +17.8% hair density, +12.3% shaft diameter

6. Analytical Methods and Quality Control

6.1 High-Performance Liquid Chromatography & Mass Spectrometry

Stability-indicating RP-HPLC (C18 or positively charged anion-exchange BIST B stationary phases) with dual-wavelength UV detection at 214 nm (peptide backbone) and 246 nm (Cu(II) coordination absorption band, ε246 ≈ 8,900 M-1cm-1) quantifies peptide purity. Electrospray ionization mass spectrometry (ESI-MS) confirms [M+H]+ at m/z 403.1 (accounting for copper isotope distribution) for the complex and [M+H]+ at m/z 341.2 for the uncomplexed GHK ligand.

6.2 Copper Stoichiometry (AAS / ICP-MS)

Atomic absorption spectroscopy (AAS) or inductively coupled plasma mass spectrometry (ICP-MS) following nitric acid digestion verifies the 1:1 molar stoichiometry of elemental copper (~15.7% Cu by weight in anhydrous GHK-Cu) and confirms the absence of unchelated free copper salts.

6.3 Microbiological Quality Control

Microbiological specifications depend on intended use. Injectable pharmaceutical-grade GHK-Cu requires sterility testing per USP <71> and bacterial endotoxin testing (Limulus amebocyte lysate, LAL assay) demonstrating <0.5 EU/mL or <5 EU/kg dose, ensuring absence of pyrogenic lipopolysaccharide contamination.

6.4 Vendor Analytical Disclosure for GHK-Cu Material

Because GHK-Cu is a coordination metallopeptide complex rather than an uncomplexed peptide salt, a defensible certificate of analysis must verify both the Gly-His-Lys tripeptide purity by HPLC and identity confirmed by LC-MS alongside net peptide content. The Vendor Analytical Comparison on this site grades five suppliers on whether they publish this lot-specific analytical record.

7. Research Applications and Experimental Uses

GHK-Cu is widely utilized as a reference matrikine across tissue engineering (collagen/chitosan/hydrogel functionalization), mesenchymal and hair-follicle stem cell differentiation assays, cellular senescence and Connectivity Map transcriptomics, macrophage M1-to-M2 polarization assays, and reconstructed human epidermis (RHE) barrier models.

8. Preclinical & Topical Experimental Concentrations

In laboratory and dermatological research models, GHK-Cu concentrations are stratified by assay system (in vitro picomolar-to-nanomolar cell culture vs. topical hydrogel/liposomal formulations):

Table 5: Experimental Concentrations by Research Modality Literature summary of published study doses, routes, and schedules.
Experimental Modality Typical Concentration / Dose Schedule in Study Duration Primary Research Endpoint
In Vitro Fibroblast / Keratinocyte Culture 0.1 – 10 nM Continuous media supplementation 24–72 hours Procollagen I/IV, decorin, & integrin expression
In Vitro Transcriptomic (CMap) Profiling 1 μM Single exposure 6–48 hours Genome-wide microarray / RNA-seq analysis
Preclinical Rodent Systemic Models 1–10 mg/kg IP or SC in animal model 1–3 weeks Remote wound healing & aged mouse spatial learning
Topical Dermal / RHE Formulations 0.05–1.0% (0.5–10 mg/mL) Topical application 4–12 weeks Dermal ultrasound thickness, TEWL, collagen IHC
Topical Wound Hydrogels / Dressings 0.1–0.5% in collagen/HPMC matrix Daily dressing change 10–28 days Ischemic & diabetic wound re-epithelialization

9. Storage and Stability

Lyophilized GHK-Cu powder should be stored at -20°C to -80°C under dry, desiccated conditions in tightly sealed vials, where it maintains >98% purity for ≥24 months. Aqueous stock solutions should be maintained within the optimal pH window of pH 5.5–7.5 at 2–8°C and protected from competing divalent metal chelators such as EDTA.

10. Safety Profile, Copper Metabolism, and Contraindications

In porcine toxicology studies, GHK-Cu exhibited a therapeutic index exceeding 250-fold (1.1 mg/kg systemic wound-healing dose vs. acute hypotensive threshold). Because GHK-Cu delivers bioavailable copper (~15.7% elemental Cu by weight), experimental and clinical protocols note the following contraindications and interactions:

  • Wilson's Disease (Absolute Contraindication): Autosomal recessive ATP7B copper-transport disorder resulting in hepatic and neurological copper overload; any exogenous copper complex is strictly contraindicated.
  • Active Malignancy Caution: Due to VEGF and bFGF angiogenic stimulation, pro-angiogenic matrikines are excluded in active tumor models outside dedicated oncology studies.
  • Chelator Interactions: Divalent metal chelators (penicillamine, trientine, EDTA) strip Cu(II) from the GHK coordination sphere, abolishing metallopeptide activity.

11. Literature Review and Key Citations

Future research directions including receptor identification, epigenetic mechanism elucidation, and combination matrikine studies aim to expand mechanistic understanding of GHK-Cu:

  1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 30087896
  2. Campbell JD, McDonough JE, Zeskind JE, et al. The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health. Oxid Med Cell Longev. 2012;2012:324832. PMID: 22737174
  3. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. PMID: 3169264
  4. Kang YA, Choi HR, Na JI, et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res. 2009;301(4):301-306. PMID: 19288266
  5. Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31. PMID: 15655171
  6. Cangul IT, Gül M, Sahin N, et al. Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests. J Cosmet Dermatol. 2023;22(6):1846-1854. PMID: 37062921
  7. Conato C, Gavioli R, Guerrini R, et al. Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity. Biochim Biophys Acta. 2001;1526(2):199-210. PMID: 11978808
  8. Ahmed N, Barker G, Oliva K, et al. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery. Pharm Dev Technol. 2016;21(2):173-181. PMID: 25384620

12. Conclusion

GHK-Cu (C14H24N6O4·Cu, MW 402.92 g/mol, CAS 89030-95-5) is a well-characterized endogenous human matrikine-copper(II) complex whose square-planar coordination geometry enables femtomolar copper binding, targeted delivery of Cu(II) to lysyl oxidase and SOD1, picomolar-to-nanomolar stimulation of collagen and decorin synthesis, and modulation of over 4,000 human genes in Connectivity Map datasets.